Skip to main content
Jafron Biomedical Co.,Ltd. logo

Jafron Biomedical Co.,Ltd. — Investor Relations & Filings

Ticker · 300529 ISIN · CNE100002995 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 1,842 across all filing types
Latest filing 2025-04-15 Notice of Dividend Amou…
Country CN China
Listing Shenzhen Stock Exchange 300529

About Jafron Biomedical Co.,Ltd.

https://www.jafron.com

Jafron Biomedical Co.,Ltd. specializes in the research, development, and manufacturing of biomaterials and equipment for blood purification. The company is a primary provider of hemoperfusion technology, focusing on the production of adsorbent cartridges designed to remove specific toxins and inflammatory mediators from the bloodstream. Its core product portfolio includes the HA series of hemoperfusion cartridges, which are applied in clinical settings for end-stage renal disease, acute poisoning, critical care, and liver failure. Beyond consumables, the company develops blood purification machines and integrated treatment systems. These solutions target clinical applications in nephrology, intensive care, and hepatology. By leveraging advanced resin adsorption technology, the company provides specialized extracorporeal blood treatment options aimed at improving patient outcomes in complex medical conditions.

Recent filings

Filing Released Lang Actions
关于2024年度利润分配预案的公告
Notice of Dividend Amount Classification · 95% confidence The document is an announcement from a company regarding its 2024 annual profit distribution plan, including details on dividends, share repurchases, and related financial figures. It includes board and supervisory committee approvals and mentions that the plan requires shareholder approval at the upcoming annual general meeting. The document does not contain a full annual report or detailed financial statements but focuses on the profit distribution proposal and related corporate governance procedures. This fits the category of a Notice of Dividend Amount (DIV), as it announces the dividend amount, payment basis, and related shareholder information. The document length is about 4,142 characters, which is consistent with an announcement rather than a full report.
2025-04-15 Chinese
关于注销部分股票期权的公告
Regulatory Filings Classification · 95% confidence The document is an official announcement from a company regarding the cancellation of a portion of stock options under its 2022 stock option incentive plan. It details the number of stock options cancelled, the reasons for cancellation (such as employees leaving and unmet performance targets), and the approvals from the board and supervisory committee. The document includes legal opinions and references to meetings where the cancellation was approved. It does not contain financial statements or detailed financial performance data, but rather focuses on a corporate action related to stock options. This type of announcement fits best under the category of Regulatory Filings (RNS), as it is a regulatory disclosure about stock option cancellations and related corporate governance matters, not a full financial report or a management report. The document length (5382 characters) and content confirm it is not a brief announcement of a report publication (RPA) but a substantive regulatory announcement. Therefore, the appropriate classification is Regulatory Filings (RNS).
2025-04-15 Chinese
2024年年度报告
Annual Report Classification · 100% confidence The document is titled as the "2024 年年度报告全文" (2024 Annual Report Full Text) of 健帆生物科技集团股份有限公司. It contains detailed sections including company overview, financial data, management discussion and analysis, corporate governance, environmental and social responsibility, shareholding changes, bond information, and a full financial report section. The document includes audited financial statements, signatures of company officers and auditors, and comprehensive financial and operational data for the fiscal year 2024. The length is substantial (15,000 characters), indicating it is the full report rather than a brief announcement. The presence of detailed financial metrics, management analysis, and governance information confirms this is the official annual report covering the full fiscal year and company performance. Therefore, the document fits the definition of an Annual Report (10-K). FY 2024
2025-04-15 Chinese
关于参加深圳证券交易所成长新启航民企百舸竞中流2024年度集体业绩说明会的公告
Regulatory Filings Classification · 95% confidence The document is an announcement about the company's participation in a collective performance explanation meeting organized by the Shenzhen Stock Exchange. It includes details about the meeting time, location, format, and how investors can submit questions. The document is short (784 characters) and does not contain any financial statements or detailed financial data. It is not the actual performance report but an announcement related to an event where performance will be discussed. Therefore, it fits best as a Regulatory Filing (RNS) since it is a general regulatory announcement and does not fit other specific categories like Earnings Release or Investor Presentation.
2025-04-15 Chinese
关于控股子公司接受财务资助暨关联交易的公告
Regulatory Filings Classification · 95% confidence The document is an announcement regarding a related party transaction where a controlling subsidiary received financial assistance from a related party. It details the terms of the loan, the parties involved, the approval process by the board and supervisory committee, and confirms compliance with regulatory requirements. The document is relatively short (2053 characters) and focuses on disclosure of a specific transaction rather than presenting financial statements or comprehensive financial data. It does not contain financial results, audit opinions, or detailed management discussion. Therefore, it fits best as a Regulatory Filing (RNS) because it is a regulatory disclosure announcement about a related party transaction and not a full financial report or other specific filing type.
2025-04-15 Chinese
关于2025年第一季度健帆转债转股情况的公告
Regulatory Filings Classification · 95% confidence The document is an official announcement from a company regarding the status of its convertible bonds (健帆转债) for the first quarter of 2025. It details the bond issuance, listing, conversion price adjustments over time, and the fact that no conversions occurred in the first quarter of 2025. It also provides updated share capital structure information as of March 31, 2025. The document is regulatory in nature, providing updates on bond conversion and share capital changes, but it does not contain comprehensive financial statements or detailed financial performance data. It is not an annual or quarterly report, nor is it a call transcript or management report. It is a formal disclosure about convertible bond conversion status and share capital changes, fitting the category of a Regulatory Filing (RNS) as it is a regulatory announcement that does not fit other specific categories.
2025-04-02 Chinese

Browse filings by year

11 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.